MétaCan
Menu
← Back to cohort

Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time Series Analysis

2020· preprint· en· W4249647418 on OpenAlexaboutno aff
George Dranitsaris, Carlo DeAngelis, Blake Pearson, L. A. McDermott, Bernd Pohlmann Eden

Bibliographic record

Venuenot available
Typepreprint
Languageen
FieldMedicine
TopicCannabis and Cannabinoid Research
Canadian institutionsnot available
Fundersnot available
KeywordsOxycodoneHydrocodoneMedicineHydromorphoneTramadolPregabalinMedical prescriptionCannabisLegalizationOpioidCodeineFentanylMorphineAnesthesiaPsychiatryInternal medicinePharmacologyAnalgesic

Abstract

fetched live from OpenAlex

Rationale, aims and objectives: Between January 2016 and March 2019, an estimated 12,800 Canadians died from an opioid-related overdose. A contributing factor has been the abuse of legally obtained prescription opioids. The use of plant derived cannabinoids for chronic pain has been growing in recent years. In October 2018, recreational cannabis became legal in Canada, which resulted in increased access and a reduction in the stigma associated with usage. The purpose of this study was to assess trends in the amount and total cost of opioid prescribing in Canada prior to and following cannabis legalization. Methods: National monthly prescription claims data for public and private payers were obtained from January 2016 to June 2019. The drugs evaluated consisted of morphine, codeine, fentanyl, hydrocodone, hydromorphone, meperidine, oxycodone, tramadol and the non-opioids gabapentin and pregabalin. All opioid volumes were converted to a mean morphine equivalent dose (MED)/claim. Gabapentin and pregabalin claims data were analyzed separately from the opioids. Time series regression modelling was undertaken with dependent variables being mean MED/claim and total monthly spending. The slopes of the time series curves were then compared pre vs. post cannabis legalization. Results: Over the 42-month period, the mean MED/claim declined within public plans (p < 0.001). However, the decline in MED/claim was 5.4 times greater in the period following legalization (4.1 vs. 22.3 mg/claim). Total monthly opioid spending by public payers was also reduced to a greater extent post legalization ($95,000 vs. $267,000 per month). The findings were similar for private drug plans; however, the absolute drop in opioid use was more pronounced (30.8 mg/claim pre vs. 76.9 mg/claim post). Over the 42-month period, gabapentin and pregabalin usage also declined. Conclusions: Our findings support the hypothesis that easier access to cannabis for pain may reduce opioid use for both public and private drug plans.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.059
Threshold uncertainty score0.154

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.007
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0030.009
Science and technology studies0.0010.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.311
Teacher spread0.285 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same topicCannabis and Cannabinoid Research→French-language works237,207→